Navigation Links
Phosphagenics to Commence Phase 2 TPM/Insulin Clinical Trial
Date:9/12/2007

MELBOURNE, Australia, Sept. 12 /PRNewswire-FirstCall/ -- Phosphagenics Limited (ASX: POH, AIM: PSG, OTCQX: PPGNY) today announced that it has received approval to commence a Phase 2 clinical trial of its proprietary transdermal insulin, TPM/Insulin.

The Phase 2 trial, to commence this month, will be single-blinded, placebo controlled, three way cross-over and randomized in up to 60 patients, with the endpoint of assessing the efficacy of TPM/Insulin in patients with type 1 and type 2 diabetes.

The trial, which will be conducted by CMAX at The Royal Adelaide Hospital under the guidance and supervision of Dr. Sepehr Shakib, Director, Department of Clinical Pharmacology, Royal Adelaide Hospital and Associate Professor William Hsu of the Joslin Diabetes Centre, Harvard Medical School, is expected to be completed in the first half of 2008.

Dr. Esra Ogru, Executive Vice President of Research and Development at Phosphagenics, said: "We are excited to reach this milestone and advance our technology for the transdermal delivery of insulin to Phase 2 trials.

"Our Phase 1b trial, conducted by CMAX at the Royal Adelaide Hospital, showed that our TPM/Insulin formulation safely penetrated through human skin and delivered insulin into the blood stream over a sustained period of time without adverse reactions.

"Phosphagenics' aim is to provide a safe and effective transdermal insulin to treat diabetes," concluded Dr. Ogru.

About Phosphagenics Limited

Phosphagenics is a Melbourne-based, globally driven biotechnology company focused on the discovery of new and cost effective ways to enhance the bioavailability, activity, safety and delivery of proven pharmaceutical and nutraceutical products. The Company's core technology is built around the science and application of phosphorylation, a process where the addition of a phosphate group has been found to enhance the bioavailability, activity and safety of existing pharmaceuticals and nutr
'/>"/>

SOURCE Phosphagenics Limited
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Phosphagenics Announces Positive Proof of Concept Results from Studies Utilizing Companys Dermal Drug Delivery Technology
2. Phosphagenics to Commence Phase 1b Transdermal Insulin Clinical Trial in Second Quarter
3. LANI completes Phase I in Japan and to commence Phase I in UK
4. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
5. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 24, 2014  Novastem, a leader in regenerative ... in its study for ischemic stroke at Clinica ... ischemic strokes account for 87 percent of all ... in the study, entitled "Internal Research Protocol in ... Stem Cells and Intrathecal Administration of Neural Stem ...
(Date:12/24/2014)... China, Dec. 24, 2014 /PRNewswire/  -- Tianyin Pharmaceutical ... pharmaceutical company that specializes in the patented biopharmaceutical, ... active pharmaceutical ingredients (API) released unaudited preliminary financial ... 2015. Fiscal Year 2015 Ended September ... $9.7 million compared with $14.7 million in 1Q14 ...
(Date:12/24/2014)...  The International Trade Commission (ITC) issued its final decision ... In a notice issued on December 23, the ITC ruled ... its humidifier was invalid. BMC President, James ... very excited with the ITC,s decision in this case. This ... since the very beginning on the key patents in the ...
Breaking Medicine Technology:Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 2Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 3Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 4TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 2TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 3TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 4TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 5TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 6TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 7TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 8TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 9TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 10TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 11TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 12ITC Final Decision Goes Against ResMed (RMD) Monumental Win for 3B/BMC 2
... Janssen Alzheimer Immunotherapy, together with its collaborator ... pleased to announce the Alzheimer,s Association™, the world,s ... and research, as a new beneficiary of ... Everything campaign. Through this campaign, mountaineer and ...
... DIEGO, May 10, 2011 /PRNewswire/ -- Pf enex ... Pf enex Expression Technology™ platform, announced today a ... the global biologics business of AstraZeneca. The agreement provides ... Technology and scientific resources for the development of bioprocesses ...
Cached Medicine Technology:Alzheimer's Association Salutes Advocate and Mountaineer Now Climbing Everest as Part of The 7 Summits Climb for Alzheimer's 2Alzheimer's Association Salutes Advocate and Mountaineer Now Climbing Everest as Part of The 7 Summits Climb for Alzheimer's 3Alzheimer's Association Salutes Advocate and Mountaineer Now Climbing Everest as Part of The 7 Summits Climb for Alzheimer's 4Pfenex Announces Strategic Collaboration With MedImmune for the Use of Pfenex Expression Technology™ 2
(Date:12/25/2014)... Each year trauma accounts for approximately 42 ... across the nation (according to the Centers for ... Hospital Ambulatory Medical Care Survey collected data from ... They estimated that there were between 3.5 and 4.4 ... diagnosis of broken bone or fracture. , When ...
(Date:12/24/2014)... Epigenetics finds applications in a large ... drug discovery, developmental biology, and research for metabolic and ... the most widely used techniques for the discovery and ... of cancer is rapidly growing worldwide. In 2012, there ... deaths, and 32.6 million people living with cancer (within ...
(Date:12/24/2014)... (PRWEB) December 24, 2014 New studies reveal ... to hearing loss related depression (March 6, 2014, JAMA Otolaryngology*). ... gradual hearing loss (about 50 percent according to recent polls) ... effect on how a person feels and relates to the ... overall improvements are also made by way of:, ...
(Date:12/24/2014)... December 25, 2014 Today, Yunx.co.uk, a ... evening dresses and other special occasion outfits, unveils ... models are offered at discounted prices, up to 80% ... young ladies with their fashionable designs, gorgeous looks and ... exception. The business is devoted to designing and offering ...
(Date:12/24/2014)... HealthDay Reporter TUESDAY, Dec. 23, 2014 ... sex for one year will be allowed to donate blood in ... a 31-year ban on donations from men who have sex with ... intention to release a new draft guidance in early 2015 that ... The FDA is changing its policy based on data from ...
Breaking Medicine News(10 mins):Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 2Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 3Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 4Health News:Global Epigenetics Market Was Valued at $413.24 Million in 2014 - New Research Report by MarketsandMarkets 2Health News:Global Epigenetics Market Was Valued at $413.24 Million in 2014 - New Research Report by MarketsandMarkets 3Health News:Recent Studys Underscore the Fact That One of the Best Gifts to Give This Holiday Season is a Hearing Test 2Health News:Recent Studys Underscore the Fact That One of the Best Gifts to Give This Holiday Season is a Hearing Test 3Health News:Recent Studys Underscore the Fact That One of the Best Gifts to Give This Holiday Season is a Hearing Test 4Health News:Recent Studys Underscore the Fact That One of the Best Gifts to Give This Holiday Season is a Hearing Test 5Health News:Recent Studys Underscore the Fact That One of the Best Gifts to Give This Holiday Season is a Hearing Test 6Health News:Yunx.co.uk Unveils 65 New Bridesmaid Dresses for the UK market 2Health News:FDA to Lift Ban on Blood Donations by Gay Men 2Health News:FDA to Lift Ban on Blood Donations by Gay Men 3
... or GAD, have abnormalities in the way their brain unconsciously ... School of Medicine study, and the study authors say the ... our understanding of how emotion is regulated in everyday life. ... American Journal of Psychiatry. According to the National ...
... , ... Dr. Peter H.R. Green M.D. for an enlightening discussion on celiac disease, one of the ... unknowingly has celiac. Dr. Green diagnoses over 2,400 celiac patients a year, one being day-time ... ...
... study found , WEDNESDAY, Feb. 10 (HealthDay News) -- Damage ... thinking and feeling in patients, a finding that adds new ... makeup of the mind, researchers say. , The findings, published ... based on research in patients who had surgery to remove ...
... , PUYALLUP, Wash. , Feb. 10 ... and the American Recovery and Reinvestment Act became household ... imaging and data management integration project with interoperability provider ... for MINW patients even after the completion of the ...
... Oncology (ASO), the official journal of the Society ... with the American Society of Breast Surgeons beginning in ... leading monthly publication that features original articles on the ... Dr. William Curtis, Executive Vice President for Clinical ...
... National Poll Finds Voters Prefer Tobacco Tax to Other Tax ... Raising Iowa ,s cigarette tax by $1 ... new annual revenue to help close the state,s budget shortfall, while ... released today by a coalition of public health organizations. , (Logo: ...
Cached Medicine News:Health News:People with anxiety disorder less able to regulate response to negative emotions, study shows 2Health News:People with anxiety disorder less able to regulate response to negative emotions, study shows 3Health News:Multi-Award Winning Author Tina Turbin Interviews Special Guest Dr. Peter H.R. Green, M.D. On The Thrive in Balance Radio Show 2Health News:Physical Changes in Brain Linked to Altered Spirituality 2Health News:Medical Imaging Northwest Completes Phase I of Its Healthcare IT Integration to Maintain Patient Care Improvements 2Health News:Medical Imaging Northwest Completes Phase I of Its Healthcare IT Integration to Maintain Patient Care Improvements 3Health News:Annals of Surgical Oncology adds new society affiliation 2Health News:New Report: $1 Cigarette Tax Increase Would Raise $65.3 Million for Iowa and Cut Youth Smoking 2Health News:New Report: $1 Cigarette Tax Increase Would Raise $65.3 Million for Iowa and Cut Youth Smoking 3
Lyphochek Urine Bone Markers Control is a bilevel human urine based control designed to monitor tests for urinary markers of osteoporosis management and bone resorption....
Lyphochek Maternal Serum Control is a trilevel product with analytes at clinically significant levels to monitor maternal serum analysis....
... Immunoassay Plus Control is a ... in today's busy immunoassay laboratory. ... this human serum based control ... separate control products for immunoassay ...
... NsD Nucleic Sample Detection Platform provides fully ... The new platform for molecular pathology ... (CE), with software features that deliver a ... Vidiera NsD has the capacity to run ...
Medicine Products: